IDEAYA Biosciences Q2 net loss widens to $112.5 million on higher R&D spending
IDEAYA Biosciences reported second-quarter 2026 results, with a net loss of $112.5 million, up from $98.5 million in the first quarter, as collaboration revenue rose to $8.9 million and R&D expenses increased to $108.7 million. The company had about $1.24 billion in cash, cash equivalents and marketable securities as of June 30, 2026, and said its cash runway guidance into 2030 is unchanged.
Key points
- Net loss per share was $1.22 for the quarter, compared with $1.11 in the first quarter of 2026.
- Collaboration revenue was $8.9 million, up from $6.6 million in the first quarter of 2026.
- The darovasertib combination met the primary endpoint in the OptimUM-02 trial, with median progression-free survival of 6.9 months versus 3.1 months in the comparator arm; an NDA filing is underway with completion expected in the second hal
- Net proceeds of approximately $323.4 million from a June 2026 public offering contributed to the higher cash balance.
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 04, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.